Authored By: Sarah
17 Jun 2024

 Migraine Drugs Market to grow by USD 1.34 billion between 2024-2028

According to a research report “ Migraine Drugs Market” by End-user (Hospitals, Retail, Online) Type (Preventive, Abortive) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1.34 billion at a CAGR of  6.36% during the forecast period. The global migraine drugs market experiences significant growth due to the rising prevalence of migraine, particularly in North America. This neurological condition, which often manifests during puberty or young adulthood, is a major health concern. Factors contributing to its onset include medication overuse, leading to medication-overuse headache (MOH), as well as lifestyle factors such as lack of sleep, hunger, weather changes, excessive sensory stimulation, and stress. Overuse of pain-relief medicines can exacerbate the issue, resulting in disabling conditions..

Browse market data tables, figures, and in-depth TOC on “Migraine Drugs Market” by End-user (Hospitals, Retail, Online) Type (Preventive, Abortive) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By End-user, the Hospitals segment is projected to dominate the market size in 2024.

In the global migraine drugs market, the preventive segment is experiencing robust growth due to its ability to decrease attack frequency and severity. This segment employs both off-label and generic medications, such as beta-blockers like propranolol and atenolol. Regular intake of preventive drugs enhances the efficacy of symptom-relieving medicines during migraine episodes. Notably, beta-blockers, antiepileptics like topiramate and divalproex, and CGRP blockers or receptor antagonists are utilized for migraine prevention.

By Type, Preventive  segment is expected to hold the largest market size for the year 2024.

The global migraine drugs market's hospitals segment is experiencing robust growth, driven by the rising prevalence and diagnosis of migraine, as well as the expansion of public and private specialty healthcare facilities. Major hospitals and clinics, characterized by advanced medical infrastructure, are significant consumers of high-quality medical products and consumables in bulk. Notable advancements in migraine treatment, such as the FDA's April 2023 approval of QULIPTA (atogepant) for preventive migraine treatment in adults, are anticipated to fuel market expansion during the forecast period.

North America is forecasted to hold the largest market size by region in 2024.

In the North American market for migraine drugs, robust growth is attributed to a sophisticated healthcare infrastructure delivering top-tier migraine treatments via clinics and hospitals. Healthcare spending escalations in nations like the US and Canada further fuel market expansion. Key players, including Amgen, Eli Lilly and Company, and Novartis, dominate the North American landscape, with strategic alliances bolstering the commercialization of migraine therapeutics. The region's market is fortified by an increasing number of FDA-approved medications for migraine treatment.

The Migraine Drugs Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • Endo International Plc
  • GlaxoSmithKline Plc
  • H Lundbeck AS
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Neurelis Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Winston Pharmaceuticals Ltd.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Migraine Drugs Market encompasses a range of therapeutics designed to alleviate the symptoms and manifestations of migraine, a neurological condition characterized by sensory disturbances, including vomiting, nausea, and loss of appetite. Migraines can also present with olfactory, auditory, and visual disturbances, such as phonophobia, photophobia, and osmophobia. Migraines are often associated with vascular diseases, cardiac diseases, and pulmonary diseases. The younger generation, with their sedentary lifestyles and increased patient awareness, is driving the demand for effective migraine treatments. The Migraine Drugs Market includes anticonvulsant drugs, antipsychotics, analgesics, and pain-relieving medications. These therapeutics work by targeting the nervous system, specifically the olfactory groove and the bloodstream, to mitigate the symptoms of migraines. Migraines can also manifest as neurological medical diseases, such as migraine with aura, migraine without aura, and status migrainosus. Effective management of these conditions requires a comprehensive approach, including lifestyle modifications and pharmacological interventions. In conclusion, the Migraine Drugs Market offers a diverse range of therapeutics to address the complex and multifaceted nature of migraines. These drugs aim to provide relief from the debilitating symptoms of migraines, improving the quality of life for those affected.

Market Research Overview

The Migraine Drugs Market encompasses a range of therapeutics designed to prevent and alleviate the symptoms of migraines. These drugs include beta blockers, anti-epileptics, antidepressants, oral preventive treatments like triptans, and pain-relieving medications. The pathophysiology of migraines involves various etiologies, including vascular diseases, pulmonary diseases, cardiac diseases, neurological manifestations, and viral infections. Chronic migraines, affecting mostly females, can lead to sensory disturbances, loss of appetite, vomiting, nausea, osmophobia, phonophobia, and photophobia. Preventive treatments are essential for managing chronic effects, such as depression and anxiety. Small molecules and acute therapy are crucial in providing analgesia for headaches caused by dehydration, fever, or other triggers. Anticonvulsant drugs and antipsychotics are also employed in certain cases. The younger generation, with sedentary lifestyles and increasing patient awareness, is driving the demand for effective migraine drugs.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!